Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses a new oral compound, Selinexor and how it can be safely combined with different drugs for efficacy at the 2017 American Society of Hematology.
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses a new oral compound, Selinexor and how it can be safely combined with different drugs for efficacy at the 2017 American Society of Hematology.